juniper pharmaceuticals inc k may    am  seeking alphasign in  join nowgo»juniper pharmaceuticals inc jnpform k  current reportmay    amabout juniper pharmaceuticals inc jnpview as pdf juniper pharmaceuticals inc form k received       united states securities and exchange commission washington dc      form k     current report pursuant to section  or d of the securities exchange act of  date of report date of earliest event reported may       juniper pharmaceuticals inc exact name of registrant as specified in its charter       delaware       state or other jurisdiction of incorporation   commission file number   irs employer identification no    arch street suite  boston massachusetts    address of principal executive offices   zip code registrants telephone number including area code       check the appropriate box below if the form k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions  see general instruction a below     ☐ written communications pursuant to rule  under the securities act  cfr      ☐ soliciting material pursuant to rule a under the exchange act  cfr a     ☐ precommencement communications pursuant to rule db under the exchange act  cfr db     ☐ precommencement communications pursuant to rule ec under the exchange act  cfr ec indicate by check mark whether the registrant is an emerging growth company as defined in rule  of the securities act of  or rule b of the securities exchange act of  emerging growth company    ☐ if an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section a of the exchange act    ☐       item  results of operation and financial condition on may   juniper pharmaceuticals inc the company issued a press release announcing the financial results for the threemonth period ended march   entitled juniper pharmaceuticals reports first quarter  financial and operating results the press release a copy of the press release is furnished as exhibit  hereto and is incorporated herein by reference the information contained in this current report on form k including exhibit  shall not be deemed filed for the purposes of section  of the united state securities exchange act of  as amended or otherwise subject to the liability of section  furthermore the information shall not be deemed incorporated by reference into any registration statement or any other filing under the united states securities act of  as amended except as shall be expressly set forth by specific references in such filings item  departure of directors or certain officers election of directors appointment of certain officers compensatory arrangements of certain officers b on may   frank c condella jr notified the board of directors board of juniper pharmaceuticals inc the company that he will not stand for reelection when his current term expires at the companys  annual meeting of stockholders mr condellas decision was not the result of any disagreement with the company on any matter relating to the companys operations policies or practices item  financial statements and exhibits d exhibits   exhibit no    description     press release dated may   entitled juniper pharmaceuticals reports first quarter  financial and operating results furnished herewith pursuant to the requirements of the securities exchange act of  the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized   juniper pharmaceuticals inc   by   s jeffrey e young   name   jeffrey e young   title   senior vice president finance chief financial officer and treasurer date may   exhibit index   exhibit no    description     press release dated may   entitled juniper pharmaceuticals reports first quarter  financial and operating results furnished herewith exhibit    click to enlarge juniper pharmaceuticals reports first quarter  financial and operating results revenue from core business increased  yearoveryear crinone ® revenues increased  and juniper pharma services revenues rose  in local currency compared to first quarter of  boston may    juniper pharmaceuticals nasdaqjnp a womens health therapeutics company today announced financial results for the threemonth period ended march   cash and cash equivalents were  million at march   a  increase from december   we continue to execute on our strategy to leverage our solid financial position and grow the core business the company maintains a fiscally disciplined approach to developing our portfolio of differentiated therapeutics that address unmet and underserved medical needs in womens health said alicia secor chief executive officer we expect to be in a position to file up to three inds with the us food and drug administration in the first half of  pending completion of indenabling activities for each program our strong balance sheet ensures that we will have sufficient capital to fund operations and development through achievement of these planned milestones added ms secor the company plans to prioritize development of its portfolio and may also seek partnerships to support the advancement of one or more of its product candidates through nondilutive financing in addition the company continues to explore external opportunities to expand its existing product pipeline and pursue additional partnerships advancements on lead formulations for the companys pipeline of intravaginal ring ivr candidates continue on track for the following        jnp oxybutynin ivr for overactive bladder      jnp estradiol  natural progesterone ivr for symptoms of menopause and        jnp natural progesterone ivr for the prevention of preterm birth ptb in women with a short cervical length at midpregnancy this first quarter of  was marked by the continued growth of our core business said jeff young chief financial officer at juniper crinone product revenues were up  and revenues from juniper pharma services increased  on a local currency basis compared to the first quarter of  we are in a strong financial position to achieve our objectives first quarter financial results first quarter total revenues increased  to  million compared with  million for the quarter ended march   first quarter  revenues include  million of royalty revenue from allergan following the monetization of the allergan royalty stream in november  juniper no longer records royalty revenue from allergan product revenues were  million an increase of  driven by continued inmarket growth and new market sales of crinone ® progesterone gel by merck kgaa darmstadt germany service revenues from juniper pharma services were  million an increase of  million or  versus the first quarter of last year driven by new and existing customer growth gross profit increased to  million as compared to  million in the prior year quarter total operating expenses were  million in the first quarter of  a  million increase as compared to the prior year quarter juniper recorded a net loss of  million or  per diluted share in the first quarter of  compared to a net loss of  million or  per diluted share in the same period of  liquidity cash and cash equivalents were  million as of march   versus  million at december   board and committee composition matters juniper also announced today that frank condella will not seek reelection to the companys board of directors at the upcoming annual shareholder meeting as a result of which his term in office will expire upon completion of the meeting ms secor added we want to thank frank for his years of service to juniper and his commitment to the vision of the company we wish him well in his future endeavors in addition the company announced a change to its audit committee composition with ann merrifield assuming dr frank armstrongs place on the committee effective upon completion of the upcoming annual shareholder meeting conference call as previously announced junipers management will hold a conference call to discuss financial results for the first quarter ended march   as follows   date   may               time    am et             dialin numbers   toll free   us  canada or international      webcast live and archive  wwwjuniperpharmacom  under investors or click here the teleconference replay will be available approximately one hour after completion available through thursday march   at   us   canada or   international the replay access code is  the archived webcast will be available for one year via the aforementioned urls about juniper pharmaceuticals juniper pharmaceuticals inc is focused on developing therapeutics that address unmet medical needs in womens health the company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the b regulatory pathway targeted product development investments are enabled by junipers core operating business the crinone ®  progesterone gel franchise and juniper pharma services which provides highend feeforservice pharmaceutical development and clinical trials manufacturing to clients please visit  wwwjuniperpharmacom  for more information juniper pharmaceuticals is a trademark of juniper pharmaceuticals inc in the us and eu crinone ®  is a registered trademark of merck kgaa darmstadt germany outside the us and of allergan plc in the us forward looking statements this press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements relating to anticipated future financial performance the number and timing of investigational new drug ind application filings and potential clinical trials for junipers product candidates and the announcement of results from these trials the potential of junipers intravaginal ring ivr technology to improve the delivery of therapeutics to women junipers ability to leverage the b pathway for product candidates junipers ability to complete business development transactions including new product acquisitions andor new collaborations regarding junipers ivr technology and the expectation that the core operating business will enable targeted product development investments management believes that these forwardlooking statements are reasonable as and when made however such forwardlooking statements involve known and unknown risks uncertainties and other factors that may cause actual results to differ materially from those projected in the forwardlooking statements these risks and uncertainties include but are not limited to risks associated with the drug development process generally including the timely completion of prototype development and planned indenabling and sheep studies risks associated with the outcomes of the prototype formulation development efforts and planned indenabling and sheep studies and whether they support further development of our product candidates risks associated with the regulatory review process including the risk that the fda does not ultimately accept our proposed clinical program for jnp the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies or following commercial launch if such product candidates are approved risks associated with obtaining maintaining and protecting intellectual property risks associated with juniper pharmaceuticals ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties the risk of competition from currently approved therapies and from other companies developing products for similar uses risks associated with juniper pharmaceuticals ability to manage operating expenses andor obtain additional funding to support its business activities and risks associated with juniper pharmaceuticals dependence on third parties for a discussion of certain risks and uncertainties associated with juniper pharmaceuticals forwardlooking statements please review the companys reports filed with the sec including but not limited to its annual report on form k and subsequent filings with the sec readers are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date on which they are made these statements are based on managements current expectations and juniper pharmaceuticals does not undertake any responsibility to revise or update any forwardlooking statements contained herein except as expressly required by law investor contact argot partners laura perry or heather savelle  lauraargotpartnerscom heatherargotpartnerscom to receive junipers press releases sec filings or calendar alerts by email   click here       follow us on   linkedin   juniper pharmaceuticals inc condensed consolidated balance sheets unaudited in thousands        march       december                  assets       cash and cash equivalents               accounts receivable net                 inventories                 prepaid expenses and other current assets                                   total current assets                 property and equipment net                 intangible assets net                 goodwill                 other assets                                   total assets                                 liabilities contingently redeemable preferred stock and stockholders equity       accounts payable               accrued expenses and other                 deferred revenue                 current portion of longterm debt                                   total current liabilities                 longterm debt net of current portion                 other noncurrent liabilities                                   total liabilities                                   commitments and contingencies       series c preferred stock                 total stockholders equity                                   total liabilities contingently redeemable preferred stock and stockholders equity                                 juniper pharmaceuticals inc condensed consolidated statements of operations unaudited in thousands except per share data        three months ended march                 revenues      product revenues              service revenues                royalties                                   total revenues                cost of product revenues                cost of service revenues                                 total cost of revenues                gross profit                operating expenses      sales and marketing                research and development                general and administrative                                 total operating expenses                loss from operations                interest expense net                other income net                                 loss before income taxes                provision for income taxes                  net loss                               diluted net loss per share                               diluted weighted average shares outstanding                                 basic net loss per share                               basic weighted average shares outstanding                                 jnp stock quote  juniper pharmaceuticals inc common stock price  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  jnp juniper pharmaceuticals inc common stock quote  summary data jnp      unch unch get jnp alerts delayed  data as of jul      find a broker to begin trading jnp now exchangenasdaq industry health care community rating jnp     edit symbol list symbol lookup real time nls trade reporting flashquotes infoquotes summary quote charts interactive charts premarket charts after hours charts revenue  eps summary company financials  view competitors  short interest company news press releases company news press releases sentiment analyst stock research stock report sec filings  holdingsinsider summary  institutional holdings  insider form  equity options premarket quotes after hours quotes company research  stockconsultant stock comparison  guru analysis annual report historical quotes call transcripts dividend history lynch analysis graham analysis validea momentum analysis fool analysis dreman analysis zweig analysis fisher analysis oshaughnessy analysis etf detail etf profile comparison charts symbol list views flashquotes infoquotes stock details summary quote realtime quote after hours quote premarket quote historical quote option chain charts basic chart interactive chart company news company headlines press releases market stream stock analysis analyst research guru analysis stock report competitors stock consultant stock comparison fundamentals call transcripts annual report income statement revenueeps sec filings short interest dividend history holdings ownership summary institutional holdings insiderssec form  closex edit symbol list enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages go now clear list dont know the stock symbol use the symbol lookup tool alphabetize the sort order of my symbols closex   symbol lookup closex investing just got easier… sign up now to become a nasdaqcom member and begin receiving instant notifications when key events occur that affect the stocks you follow access now  save stocks news pricecharts tradehistory annual report earningsreport date dynamic quotes turn off best bidask best bid is the highest price currently being offered for a block of stock best ask is the lowest price currently being asked for a block of stock na  na  year target  todays high low todays high the highest sales price the stock has achieved during the regular trading hours the intraday high todays low the lowest sales price the stock has fallen to during the regular trading hours the intraday low      share volume share volume is the number of shares of the stock traded on the listing exchange during current trading hours it does not include after hours volume   day avg daily volume this is the average share volume for the past  trading days for nasdaq stocks and  trading days for nonnasdaq stocks this field allows you to compare todays trading to the average daily volume  previous close previous close is the previous trading days last reported trade price during official trading hours    week highlow  week high is the highest sales price the stock has achieved during the regular trading hours during the most recent  week period  week low is the lowest sales price the stock has fallen to during the regular trading hours during the most recent  week period      market cap “market capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent it does not include securities convertible into the common equity securities “market capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities as applicable nasdaq does not use this value to determine compliance with the listing requirements   pe ratio pe ratio is a statistic calculated by dividing the price of a stock by the reported actual earnings per share of the issuing firm not the same as the projected pe ratio it is also called the multiple  forward pey a widely used stock evaluation measure for a security the priceearnings ratio is given by dividing the last sale price by the average eps earnings per share estimate for the specified fiscal time period the forward pe refers to the value for the next full year ne earnings per share eps the eps listed on our infoquote and summary quote page is mos rolling eps represents the portion of a companys profit allocated to each outstanding share of common stock net income reported or estimated for a period of time is divided by the total number of shares outstanding tso during that period see growth rate measures for eps our vendors methodology for the eps on the infoquote and summary quote pages follows the eps used by the majority of the analysts following the stock in many cases this is ebitda eps   annualized dividend na ex dividend date the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information na dividend payment date na current yield indicated yield represents annual dividends divided by current stock price the data is based on historical exdividend data  doesn’t include upcoming values visit the dividend history page to see the upcoming dividend information   beta beta is a volatility measurement of a stock mutual fund or etf versus a comparable benchmark like the sp  stock index a stock fund or etf with a higher beta than the sp  will rise or fall to a greater degree in contrast a stock fund or etf with a low beta will rise or fall less  nasdaq official open price nasdaq official opening price this process identifies the nasdaqspecific opening prices for nasdaqlisted issues   date of open price date of open price this field refers to the date the nasdaq official open price was disseminated for a given stock it is possible that the date will not be from the current trading day this indicates that the stock didnt trade on nasdaq during the current trading day the nasdaq official open price is updated only when the stock is traded on nasdaq jul   nasdaq official close price nasdaq official closing price nocp is a process for identifying the nasdaq marketspecific closing price for nasdaqlisted issues   date of close price this field refers to the date the nocp was disseminated for a given stock it is possible that the date will not be from the prior day this indicates that the stock didnt trade on nasdaq on the prior day the nocp is updated only when the stock is traded on nasdaq jul   community sentiment intraday chart d m m m more charting company description as filed with the sec we are a womens health therapeutic company focused on developing therapeutics that address unmet medical needs in womens health our marketed product and product development programs utilize our proprietary drug delivery technologies which we believe are suited to applications in womens health these technologies consist of our bioadhesive delivery system bds a polymer designed to adhere to epithelial surfaces or mucosa and achieve sustained and controlled delivery of active drug product and our novel intravaginal ring ivr technology we are advancing three product development programs utilizing our ivr technology which target overactive bladder hormone replacement therapy in women and prevention of preterm birth in women with short cervical length historically we have developed and brought to market several prescription and over the counter pharmaceutical products   more    risk grade where does jnp fit in the risk graph news for jnp health care sector update for  abtstjjnjjnpagntsro   pm  mt newswires health care sector update for  amrnjnpagntsro   pm  mt newswires how to better understand marketmaker price range forecasts   am  seeking alpha health care sector update for  cerujnpilmntmo   pm  mt newswires auris medical ears jumps stock adds  in session   am  zackscom  subscribe more jnp news  commentary read jnp press releases consensus recommendation analyst info annual eps est  quarterly eps est  peg ratio  mean recommendation  data is provided by zacks investment research view all view summary closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex columbia laboratories begins trading as juniper pharmaceuticals jnp columbia laboratories begins trading as juniper pharmaceuticals jnp  company updates on q revenue  apr    et from columbia laboratories inc boston april   prnewswire  effective this morning columbia laboratories inc is now juniper pharmaceuticals inc nasdaq jnp the company and its nottingham uk based subsidiary molecular profiles ltd is now juniper pharma services the companys common stock will begin trading today under the symbol jnp on the nasdaq stock exchange the single juniper brand formalizes the experience and capabilities we have built across our crinone® franchise service business and proprietary product development programs said frank condella ceo of juniper pharmaceuticals the integration of juniper pharma services has provided critical inhouse drug development expertise as well as supply chain management for crinone® while also generating cashflow to advance our proprietary drug programs the specialty pharmaceutical company has adopted a new logo with an icon featuring two interlocked rings the icon symbolizes the synergy between juniper pharma services capabilities and the companys womens health focused pipeline  additionally a new corporate website reflecting the juniper brand identity has been launched at wwwjuniperpharmacom separately the company announced that revenues for the first quarter of  are expected to exceed the prior year first quarter by more than  the growth is driven by an increase in crinone® progesterone gel shipments combined with the growth of the service business in local currency the first quarter of  will also include rd spending associated with drug development activities discussed below the company is maintaining its full year guidance of low doubledigit revenue growth the companys value creation strategy is to support the continued growth of the crinone® franchise by its partners merck serono and actavis expand and maintain a profitable service business by providing unique pharmaceutical development capabilities to global pharmaceutical customers and invest operating cash flow into a proprietary product pipeline to build longterm shareholder value  recent pipeline developments include an investigational new drug filing with the us food and drug administration for col a  lidocaine bioadhesive gel intended as an acute anesthetic for use in women undergoing transvaginal pipelledirected endometrial biopsy a phase ii randomized doubleblinded placebo controlled study that will enroll  patients at fifteen us sites will be initiated later this quarter furthermore the company recently licensed worldwide exclusive rights to a proprietary intravaginal ring technology ivr developed by renowned scientists dr robert langer from the massachusetts institute of technology and dr william crowley from massachusetts general hospital and harvard medical school the ivr technology enables the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring this patient administereddevice will be utilized as a key drug delivery platform for junipers emerging proprietary product pipeline drs langer and crowley are also serving as strategic scientific advisors to help guide junipers rd initiatives and drug development strategy about juniper pharmaceuticals juniper pharmaceuticals inc nasdaq jnp is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in womens health  juniper has a successful heritage in developing pharmaceutical products including crinone®  progesterone gel which is marketed by actavis inc in the us and by merck serono sa in over  countries worldwide  the company is uniquely positioned to leverage inhouse pharmaceutical development clinical trial manufacturing and analytical capabilities to advance an internal development pipeline while also providing valuable consultative services to its pharmaceutical industry customers  please visit wwwjuniperpharmacom for more information juniper pharmaceuticals™ and juniper pharma services™ are trademarks of juniper pharmaceuticals inc in the us and eu crinone® is a registered trademark of actavis inc in the us forward looking statements safe harbor statement under the private securities litigation reform act of  this communication contains forwardlooking statements which statements are usually indicated by the words may will plans believes expects anticipates potential should or similar expressions and which are generally not historical in nature these include all statements relating to expected financial performance and future business or product developments  management believes that these forwardlooking statements are reasonable as and when made  however such forwardlooking statements involve known and unknown risks uncertainties and other factors that may cause actual results to differ materially from those projected in the forwardlooking statements  readers are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date on which they are made these statements are based on managements current expectations and juniper pharmaceuticals does not undertake any responsibility to revise or update any forwardlooking statements contained herein except as expressly required by law  for a discussion of certain risks and uncertainties associated with juniper pharmaceuticals forwardlooking statements please review the companys reports filed with the sec including but not limited to its annual report on form k for the period ended december     contact katja buhrermbs value partners katjabuhrermbsvaluecom source columbia laboratories inc related links httpwwwjuniperpharmacom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more apr    et preview columbia laboratories inc to become juniper pharmaceuticals inc my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search juniper pharmaceuticals  specialty pharmaceutical company proprietary product pipeline  developing therapies to address unmet medical needs in women’s health juniper’s pipeline is leveraging the b regulatory pathway with new formulations of existing pharmaceuticals learn more juniper pharma services  formulation development clinical trial manufacturing ip support our nottingham uk team are established experts in a range of pharmaceutical development activitieslearn more bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one juniper pharmaceuticals inc nasdaqjnp quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancejuniper pharmaceuticals incnasdaqjnpadd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   juniper pharmaceuticals inc  public nasdaqjnp   watch this stock      jul   close nasdaq realtime data  disclaimer currency in usd range     week    open  vol  avg  mkt cap m pe  divyield      eps  shares m beta  inst own  news relevance date all news for juniper pharmaceuticals inc » subscribe advertisement events add jnp to my calendars aug   q  juniper pharmaceuticals inc earnings call  pm edt  aug   q  juniper pharmaceuticals inc earnings call  pm edt  aug   q  juniper pharmaceuticals inc earnings release  pm edt  jul   juniper pharmaceuticals inc annual shareholders meeting estimated may   q  juniper pharmaceuticals inc earnings release may   q  juniper pharmaceuticals inc earnings call  more events from dailyfinance »     key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  arch st ste boston ma united states  map phone fax website links httpwwwjuniperpharmacom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry pharmaceuticals  nec more from factset » description juniper pharmaceuticals inc is a women’s health therapeutics company the company is focused on developing therapeutics that address unmet medical needs in women’s health it operates in two segments product and service the product segment is engaged in manufacturing and supplying crinone the company’s commercialized product the service segment includes product development clinical trial manufacturing and advanced analytical and consulting services as well as characterizing and developing its pharmaceutical product candidates the company’s pipeline of proprietary products includes jnp jnp and jnp jnp is developed to deliver oxybutynin for the treatment of overactive bladder in women jnp is being designed to deliver natural hormones locally to vaginal tissue jnp is being developed for the prevention of preterm birth in women with a short cervical length crinone is developed as a progesterone gel more from reuters » officers and directors james a geraghty independence chairman of the board age  bio  compensation   reuters alicia secor chief executive officer director age  bio  compensation   reuters jeffrey e young senior vice president finance chief financial officer treasurer and secretary principal financial and accounting officer age  bio  compensation   reuters nikin patel chief operating officer director age  bio  compensation   reuters bridget a martell chief medical officer age  bio  compensation   reuters frank murdoch armstrong independent director age  bio  compensation   reuters cristina csimma pharmd independent director age  bio  compensation   reuters mary ann gray phd independent director age  bio  compensation   reuters ann merrifield independent director age  bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service juniper pharmaceuticals inc private company information  bloomberg july    am et pharmaceuticals company overview of juniper pharmaceuticals inc snapshot people company overview juniper pharmaceuticals inc a women’s health therapeutic company focuses on developing therapeutics that address unmet medical needs in womens health the company develops its products using its drug delivery technologies including bioadhesive delivery system a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product and a novel intravaginal ring ivr technology it markets crinone a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency the company is also developing col a lid juniper pharmaceuticals inc a women’s health therapeutic company focuses on developing therapeutics that address unmet medical needs in womens health the company develops its products using its drug delivery technologies including bioadhesive delivery system a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product and a novel intravaginal ring ivr technology it markets crinone a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency the company is also developing col a lidocaine bioadhesive gel which is in phase b clinical trial for use as an acute use anesthetic for pain from minimally invasive gynecological procedures its products in preclinical development include jnp an oxybutynin ivr to treat overactive bladder in women jnp a product candidate with natural progesterone and natural estradiol for used in hormone replacement therapy in menopausal women and jnp a natural progesterone ivr used for the prevention of preterm birth in addition juniper pharmaceuticals inc provides pharmaceutical development clinical trial manufacturing analytical and consulting services the company was formerly known as columbia laboratories inc and changed its name to juniper pharmaceuticals inc in april  juniper pharmaceuticals inc was founded in  and is headquartered in boston massachusetts detailed description  arch streetboston ma united statesfounded in  employees phone  wwwjuniperpharmacom key executives for juniper pharmaceuticals inc ms alicia secor mba ceo president  director age  total annual compensation k dr nikin patel phd mrpharms chief operating officer and director age  total annual compensation k dr bridget a martell ma md chief medical officer age  total annual compensation k compensation as of fiscal year  juniper pharmaceuticals inc key developments juniper pharmaceuticals inc presents at boston ceo conference may  pm may   juniper pharmaceuticals inc presents at boston ceo conference may  pm venue four season boston  boylston street boston ma  united states speakers james a geraghty chairman juniper pharmaceuticals inc annual general meeting jun   may   juniper pharmaceuticals inc annual general meeting jun   at  us eastern standard time location  northern ave boston massachusetts united states agenda to elect seven members to the board of directors to ratify the appointment of pricewaterhousecoopers llp as independent registered public accounting firm for the fiscal year ending december   to conduct an advisory vote to approve the compensation of the company’s named executive officers to conduct an advisory vote on the frequency of future advisory votes on the compensation of the company’s named executive officers and to transact any other business properly brought before the annual meeting juniper pharmaceuticals inc announces resignation of frank c condella as director may   on may   frank c condella jr notified the board of directors of juniper pharmaceuticals inc that he will not stand for reelection when his current term expires at the companys  annual meeting of stockholders mr condellas decision was not the result of any disagreement with the company on any matter relating to the companys operations policies or practices similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact juniper pharmaceuticals inc please visit wwwjuniperpharmacom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close about us  juniper pharmaceuticals corporate home searchcategorieseventsnewsarchivesjuly june april october september june may march february november  about us juniper pharmaceuticals nasdaq jnp is developing therapeutics that address unmet medical needs in women’s health our current pipeline leverages the b regulatory pathway with new formulations of existing pharmaceuticals the company has a successful history in developing pharmaceutical products including crinone®  progesterone gel which is commercially available in the united states and over  countries around the world our current intravaginal ring ivr product candidates are jnp an oxybutynin ivr for the treatment of overactive bladder in women jnp a combination estrogen  progesterone ivr for menopausal symptoms and jnp a progesterone ivr for the prevention of preterm birth in women with a short cervical length at midpregnancy we are leveraging the inhouse pharmaceutical development clinical trial supply manufacturing and analytical capabilities of juniper pharma services to advance an internal product pipeline while also providing valuable intellectual propertyrelated consultative services to our pharmaceutical industry customers juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to advance a proprietary pipeline for long term value creation crinone® is a registered trademark of merck kgaa darmstadt germany outside the us and of allergan inc in the us leadership  about juniper pharma corporate home searchcategorieseventsnewsarchivesjuly june april october september june may march february november  management our senior management team provides a breadth of experience across the pharmaceutical life sciences and biopharmaceuticals industries throughout the organization — from our executive leadership team to our handson scientists to members of our finance and product development teams alicia secor mba president and chief executive officer alicia secor joined juniper pharmaceuticals as chief executive officer in august  and serves as a director of the company ms secor brings more than  years’ of leadership experience as a life sciences executive with a track record in leading businesses and advancing products from clinical development through regulatory approval commercialization and global expansion across several therapeutic areas ms secor joined juniper from zafgen inc where she was chief commercial officer and played a key role in advancing the company to a phase  precommercialization status previously ms secor served as senior vice president and chief operating officer at synagev biophamra corp and spent  years at genzyme corporation in diverse leadership roles most recently as the global general manager for the metabolic disease business during her tenure at genzyme ms secor led fully integrated businesses successfully launching products and achieving sustained revenue growth ms secor spearheaded several strategic transactions and built high performance teams resulting in consistent growth and profitability across multiple genzyme businesses including biomaterials surgical devices and injectable therapeutics prior to genzyme ms secor held positions at alkermes inc in business development and at centocor inc a johnson  johnson company in clinical and commercial operations she began her career at pfizer inc as a hospitalbased sales representative ms secor received an mba from northeastern university and a bs in healthcare administration from the university of new hampshire nikin patel phd mrpharms chief operating officer dr nikin patel cofounded and is the former chief executive officer of molecular profiles now known as juniper pharma services he joined our board of directors in september  when molecular profiles was acquired by juniper pharmaceuticals formerly columbia laboratories dr patel has over  years’ management and technical experience centered on pharmaceutical analysis and formulation development his leadership was recognized externally through the uk’s most prestigious industry accolade the queen’s award for enterprise won by molecular profiles in both  and  in the innovation category dr patel holds a first class honours degree and phd in pharmacy from the university of nottingham and is a member of the royal pharmaceutical society mrpharms dr patel is also a cofounder of locate therapeutics a specialist regenerative medicine and device company and was a director from  through  jeffrey young chief financial officer treasurer and secretary jeff young joined juniper in january  bringing over  years of financial leadership in the life sciences sector he most recently served as chief financial officer and treasurer of ovascience a global fertility company focused on new treatment options for women during his twoyear tenure at ovascience mr young led the company’s fundraising efforts and international tax strategy he was previously the cfo and treasurer of transmedics a developer of medical devices for the maintenance and transport of organs between donors and recipients before that mr young served as cfo and treasurer at lantheus medical imaging where he led and managed multiple debt offerings he joined lantheus from critical therapeutics where he was chief accounting officer early in his career he worked in various finance roles at perkinelmer inc and began his career as a certified public accountant at pricewaterhousecoopers llp mr young holds a bachelor of science in business administration from georgetown university bridget a martell ma md chief medical officer dr martell brings more than  years’ experience in clinical product development medical affairs and academia to juniper including expertise in establishing regulatory strategies for clinical programs and creating submission readiness packages before joining juniper dr martell was the founder and managing director of bam consultants which provided clinical development and medical affairs consulting services to a broad array of specialty pharmaceutical companies prior to that she oversaw the clinical product development and medical affairs activities at purdue pharma and for several business units within pfizer dr martell is a clinical professor at the yale university school of medicine and was a medical director at the albert einstein college of medicine from july  through june  dr martell holds a bachelor of science from cornell university master of arts from boston university and a doctor of medicine degree from the chicago medical school she completed her internship and residency in internal medicine was a chief resident and a robert wood johnson clinical scholar at yale university school of medicine she is board certified in both internal and addiction medicine shen luk bsc phd chief scientific officer dr shen luk has over  years of technical experience in the pharmaceutical and chemical industries since joining juniper pharma services in  dr luk has been integral in developing the company’s scientific breadth and rigor  he leads and consults on a diverse array of analytical characterization and pharmaceutical development projects over the past decade dr luk has also used his extensive analytical and characterization expertise for pharmaceutical systems to assist and consult in litigation matters surrounding intellectual property  previously dr luk spent ten years working in the chemicals industry at courtalds corporate research laboratories dr luk holds a chemistry degree and doctorate from the university of manchester’s institute of science and technology claire maddensmith bsc phd senior vice president juniper pharma services dr claire maddensmith has served at juniper pharma services  for over a decade she brings over  years of cro business and technical experience leading our commercial team and pharmaceutical development service dr maddensmith instills a consultative approach to the development of new business opportunities dr maddensmith holds a degree in chemistry and a doctorate in physical chemistry from loughborough university previously she has chaired the marketing committee of the controlled release society and served on the materials science focus group of the academy of pharmaceutical science gb  juniper pharmaceuticals  investor faq corporate homeinvestor faqwhy did juniper pharmaceuticals change its name from columbia laboratories juniper pharmaceuticals changed its name from columbia laboratories on april   to better reflect the company’s strategy of drug development as part of this transition molecular profiles a wholly owned subsidiary of juniper pharmaceuticals changed its name to juniper pharma services where is juniper pharmaceuticals’ stock traded  our common stock has traded on the nasdaq global market since february   in keeping with the company’s name change the ticker symbol changed to jnp from cbrx on april   the company previously traded on the american stock exchange under the symbol cobhow does the name change affect shareholders  stock certificates bearing the company’s former name columbia laboratories inc will remain valid please note that our ticker symbol has changed to jnp from cbrxwhen was juniper pharmaceuticals incorporated juniper pharmaceuticals formerly known as columbia laboratories inc became a delaware corporation in  who are juniper pharmaceuticals’ auditors bdo usa llpwho is juniper pharmaceuticals’ transfer agent what does a transfer agent do american stock transfer  trust company llc  maiden lane new york new york  t   a transfer agent maintains stock registries for their client companies such as juniper pharmaceuticals they issue and cancel stock certificates process and pay dividends administer dividend reinvestment programs resolve issues arising from lost or stolen certificates and answer questions from shareholders about their accounts i lost my stock certificate who do i call  questions regarding stock transfer requirements lost certificates and changes of address should be directed to american stock transfer  trust company llc  maiden lane new york new york  t  what is the company’s stock split history a for reverse split of our common stock par value  per share was effective when the market opened on august   the reverse stock split reduced the number of issued and outstanding shares of common stock from approximately  to approximately  what is the cusip number for the common stock the cusip number for the new common stock outstanding after the ticker symbol changed to jnp on april   is ldoes juniper pharmaceuticals pay a dividend  we have never declared or paid a cash dividend on our common stock and expects that our earnings will continue to be retained for use in the operation and expansion of our businesswhat is juniper pharmaceuticals’ fiscal year  juniper pharmaceuticals’ fiscal year ends on december st each year when is juniper pharmaceuticals’ annual meeting of shareholders  the  annual meeting of shareholders will be held on wednesday july   at  am edt at the godfrey hotel at  washington street in boston  click here to access junipers  annual report how do i receive more information about the company  for information about the company please contact us at irjuniperpharmacom  to receive press releases notice of sec filings and other alerts by email click herehow do i receive more information about juniper pharma services  juniper pharma services formerly known as molecular profiles is a wholly owned subsidiary of juniper pharmaceuticals based in the united kingdom please visit httpwwwjuniperpharmacompharmaservices or contact enquiryjuniperpharmacom about us  juniper pharmaceuticals corporate home searchcategorieseventsnewsarchivesjuly june april october september june may march february november  about us juniper pharmaceuticals nasdaq jnp is developing therapeutics that address unmet medical needs in women’s health our current pipeline leverages the b regulatory pathway with new formulations of existing pharmaceuticals the company has a successful history in developing pharmaceutical products including crinone®  progesterone gel which is commercially available in the united states and over  countries around the world our current intravaginal ring ivr product candidates are jnp an oxybutynin ivr for the treatment of overactive bladder in women jnp a combination estrogen  progesterone ivr for menopausal symptoms and jnp a progesterone ivr for the prevention of preterm birth in women with a short cervical length at midpregnancy we are leveraging the inhouse pharmaceutical development clinical trial supply manufacturing and analytical capabilities of juniper pharma services to advance an internal product pipeline while also providing valuable intellectual propertyrelated consultative services to our pharmaceutical industry customers juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to advance a proprietary pipeline for long term value creation crinone® is a registered trademark of merck kgaa darmstadt germany outside the us and of allergan inc in the us disclaimer  juniper pharma corporate home searchcategorieseventsnewsarchivesjuly june april october september june may march february november  disclaimer this site contains forward looking statements made pursuant to the safe harbor provisions of the private securities litigation reform act of  such statements involve risks and uncertainties including but not limited to economic competitive governmental and technological factors affecting juniper’s operations markets products and prices and other factors these factors which are discussed in the documents filed by juniper with the us securities and exchange commission may cause juniper’s results to differ materially from the statements made in this report or otherwise made by or on behalf of juniper juniper pharmaceuticals inc hereby grants you the right to download and copy any document or page published by juniper on this web site for your personal noncommercial use only provided that any copy of such document or page retains all copyright or other proprietary notices and any disclaimer contained thereon further reproduction in whole or in part or any distribution publication or modification of any part of this web site is prohibited all product names whether or not appearing in large print or with a trademark symbol logos trademarks and service marks are trademarks collectively the “trademarks” of juniper pharmaceuticals inc or its licensees or other third parties except as permitted above or to identify a product company or service no use of any trademark trade name or trade dress displayed on this web site may be made without the express and prior written permission of juniper or such third party nothing contained in this web site shall be construed as granting or conferring any license or right express or implied in to or under any trademark trade name trade dress copyright patent or proprietary right of juniper or any third party while juniper uses reasonable efforts to include accurate and current information in this site juniper makes no representation or warranty of any kind either expressed or implied regarding the accuracy or completeness of the content of this site in no event shall juniper its affiliates officers directors employees agents and representatives be liable for any direct indirect incidental consequential special exemplary punitive or other damages even if informed of the possibility of such damages juniper shall not be liable for any damages or injury resulting from your access to or inability to access this site or from your reliance on any information at this site the information contained in this site is subject to change without notice although accessible by others the product information on this site is intended for use by us residents only this site contains information about products that may or may not be available in any particular country or region of the world may be available under different trademarks in different countries and may be approved or cleared by a government regulatory body for sale or use with different indications and restrictions in different countries this site may link to other sites produced by third parties some of which are outside the us those sites may have information that is appropriate only to the particular originating country or region where the site is based you should not construe anything on the site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of the country where you are located this site may contain information related to various health and medical conditions and their treatment such information is not meant to be a substitute for the advice provided by a physician or other medical professional you should not use this information diagnosing a health or fitness problem or disease this site may provide links or references to other web sites not affiliated with juniper links to other sites are provided only as a convenience juniper is not responsible for the content of such other sites and shall not be liable for any damages or injury arising from users’ access to such sites you should not use this site or any of the fax email and mailing addresses appearing on it to send juniper confidential or proprietary information data received that is not personal including questions comments ideas and suggestions shall be deemed to be nonconfidential and juniper shall be free to disclose and use it this site may contain contact information for equity analysts and others who provide investment research coverage on juniper’s common stock juniper does not endorse the estimates or views of analysts and inclusion of this contact information should not be deemed an endorsement or confirmation of the estimates or views that such analysts may offer contact us  juniper pharma corporate home our contact details juniper pharmaceuticals  arch streetst floorboston ma united states tel     email enquiryjuniperpharmacom email clinicaltrialsjuniperpharmacom in the uk juniper pharma services  orchard placenottingham business parknottinghamng pxunited kingdom tel      fax      email enquiryjuniperpharmacom juniper pharma services is a company registered in england and wales with registration number  get directions pdf make an enquiry name email message board of directors  juniper corporate home searchcategorieseventsnewsarchivesjuly june april october september june may march february november  board of directors frank m armstrong frcpe ffpm frank condella bs pharm mba cristina csimma pharmd mhp james a geraghty – chairman mary ann gray phd ann merrifield nikin patel phd mrpharms – chief operating officer alicia secor mba – president and chief executive officer to learn more about our board of directors please click here news events  pharma services  juniper pharma t      e enquiryjuniperpharmacom social linkedin search scienceled pharmaceutical development services corporate home news searchcategorieseventsnewsarchivesjuly june april october september june may march february november  newsevents webinar – the importance of dose prediction for early drug development  weeks ago news juniper pharma services will be presenting a webinar with xenogesis the importance of dose prediction for early drug development at pm bst on thursday th july  the webinar will examine how gaining a thorough understanding of the chemical and pharmacological attributes of a drug substance through preclinical studies is paramount for providing an effective dosage form read more juniper pharma services brings psd spray dryer online  month ago news nottingham uk – juniper pharma services “the company” or “juniper” a subsidiary of juniper pharmaceuticals inc nasdaq jnp has broadened its manufacturing capabilities bringing online its new spray dryer following the successful installation and validation of the advanced manufacturing equipment at its ukbased site the contract development and manufacturing organisation cdmo has seen significant interest read more juniper pharma services expands granulation capabilities  months ago news nottingham uk – juniper pharma services “the company” a subsidiary of juniper pharmaceuticals inc nasdaq jnp has added a roller compactor to its enabling technologies platform to satisfy increasing market demand for its pharmaceutical development services the ukbased contract development and manufacturing organisation cdmo has purchased a gerteis minipactor® to expand its granulation capabilities and read more webinar – an integrated biopharmaceutics approach for effective drug development  months ago news juniper pharma services will be presenting a webinar with xenogesis an integrated biopharmaceutics approach for effective drug development at pm – pm bst on thursday th september  the webinar will examine why new drug candidates fail during development for many reasons and will be centred around undesirable absorption andor metabolism of the compound in man read more tablet press investment at juniper pharma services  year ago news nottingham uk – juniper pharma services “the company” a subsidiary of juniper pharmaceuticals inc nasdaq jnp has bolstered its tablet manufacturing capabilities following the purchase and validation of an additional tablet press the investment by the ukbased contract development and manufacturing organisation cdmo significantly extends its tablet production capacity and further strengthens the company’s ability read more juniper pharma services strengthens topicals capability  year ago news nottingham uk – juniper pharma services “the company” a subsidiary of juniper pharmaceuticals inc nasdaq jnp has reinforced its early stage topical and semisolids capability by investing in a becomix homogenizer mixer the installation and validation of the new equipment extends the company’s ability to manufacture creams ointments and semisolids to support clients’ clinical trial read more juniper pharma services scales up spraydrying capability  year ago news nottingham uk – juniper pharma services “the company” a subsidiary of juniper pharmaceuticals inc nasdaq jnp has reinforced its enabling technologies platform by making a substantial investment into its spray drying capabilities the contract development and manufacturing organisation cdmo has placed an order for a psd spray dryer which is manufactured by gea niro and read more juniper pharma services and xenogesis to head to barcelona on market visit  year ago news juniper pharma services is joining forces with xenogesis on a market visit to barcelona this march the visit which is being supported by ukti will include a tour of a number of life science companies in the barcelona area juniper pharma services and xenogesis have been working together to offer a seamless and combined service to clients read more juniper and crystec sign agreement for next generation medicines  year ago news nottingham uk – juniper pharma services a subsidiary of juniper pharmaceuticals inc nasdaq jnp will work with crystecpharma on a major multipartner project as part of the advanced manufacturing supply chain initiative amsci to help create a new platform to accelerate drug development in the future both companies will collaborate as part of this ukbased read more juniper pharma services strengthens capsule capability with xcelodose  years ago news nottingham uk – juniper pharma services a subsidiary of juniper pharmaceuticals inc nasdaq jnp has reinforced its early stage capsule filling expertise with the expansion of its xcelodose® powder microdosing system as part of its suite of gmp capabilities the move by the contract development and manufacturing organisation cdmo follows demand from its clients to read more microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft juniper pharmaceuticals  specialty pharmaceutical company proprietary product pipeline  developing therapies to address unmet medical needs in women’s health juniper’s pipeline is leveraging the b regulatory pathway with new formulations of existing pharmaceuticals learn more juniper pharma services  formulation development clinical trial manufacturing ip support our nottingham uk team are established experts in a range of pharmaceutical development activitieslearn more juniper pharmaceuticals unveils strategic and product development objectives for homemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballjuniper pharmaceuticals unveils strategic and product development objectives for pr newswirejanuary  reblogsharetweetshareboston jan   prnewswire  juniper pharmaceuticals inc jnp juniper or the company today announced plans for  that are expected to enable the company to submit investigational new drug ind applications for its hormonedelivery intravaginal ring ivr candidates in the first half of   these plans build on recent developments includingsignificant technical progress on ivr platform technology including initial data from cgmpquality prototypes demonstrating that junipers ivr achieves sustained release of progesterone and estrogennovel sheep model established for ivr evaluations beginning with jnp in which in vitroin vivo pharmacokinetic correlations were observed which can facilitate ivr design advancements with rapid testing of various formulations andpreind meeting with the us food and drug administration fda regarding the development pathway for the jnp progesterone ivr for the prevention of preterm birthwe enter  in a position of strength bolstered by our recent cash infusion from allergan and the valuable financial leadership that our new cfo jeff young brings to our growing team said alicia secor junipers president and chief executive officer  we are wellpositioned to selffund our operations including targeted investments in our internal pipeline candidates and our cdmo juniper pharma services in  while maintaining a healthy balance sheet throughout the year   our strategy is to build value by developing and bringing to market innovative therapies to meet the healthcare needs of women women represent over  of the us population yet treatment options for common conditions beyond contraception are limited ms secor continued we aim to address conditions such as menopausal symptoms overactive bladder and preterm birth but also to remove the stigma and inspire the conversations that will foster a vibrant community of healthy empowered womenjnp for preterm birth prevention in the fourth quarter of  the company held a constructive preind meeting with the fda for jnp its natural progesterone ivr in development for the prevention of preterm birth ptb in women with a short cervical length at midpregnancy scl  in the us alone the prevalence of women at risk for ptb due to scl defined as span mm is estimated to be around  the incidence of this condition is expected to rise as more physicians adopt the current medical guidelines to screen for scl in all pregnant women  there is currently no fdaapproved drug to prolong gestation in this patient populationwe look forward to further dialogue with the agency as we advance our indenabling work and seek to finalize the clinical program design for jnp noted dr bridget martell junipers chief medical officerprototype testing is underway and benefits from the concurrent work being done on jnp  juniper expects to conduct indenabling studies with jnp in  and to initiate definitive sheep studies by yearend  which among other planned activities are expected to enable an ind submission in the first half of  for jnpwith  million babies born before  weeks gestation around the world each year and  million deaths annually due to complications of preterm birth juniper will also seek scientific and regulatory input in other geographies to support development to meet the global unmet needjnp hormone replacement therapy hrt for menopauseprototype testing is also underway for jnp which employs the multisegmented capability of the juniper ivr for hrt to deliver natural estrogen and progesterone to alleviate symptoms of menopause in women  an estimated  million women are either menopausal or approaching menopause in us alone the domestic market was valued at over  billion in  comprising both pharmacycompounded and fdaapproved therapies for hrtread morethe company will focus on indenabling activities for jnp including a definitive sheep study to be initiated by yearend   an ind for jnp is also planned for the first half of jnp for overactive bladder oabbuilding on preclinical data from a recentlycompleted pilot study in a sheep model juniper is refining the cgmp formulation of jnp its oxybutynin ivr for the treatment of oab in women to address the unique properties of this moleculeoab is characterized by involuntary contraction of the detrusor muscles before the bladder is full this chronic urological condition affects an estimated  million women in the us with approximately nine million receiving pharmacologic therapy the domestic market for oab therapeutics was approximately  billion in pursuing multiple strategic opportunitiesin addition to making investments in juniper pharma services and measured development of the aforementioned ivr candidates juniper is actively exploring new strategic opportunities includingcollaborations to apply the ivr technology platform and technical expertise in polymer science with other companies therapeutic agentspartnerships for internallydeveloped candidatespipeline expansion through inlicensing or acquisition of externallydeveloped womens health therapeuticsbusiness development is a key strategic focus for  while advancing our pipeline internally we intend to leverage our many assets and maintain optionality for our programs to maximize value for shareholders ms secor concludedabout juniper pharmaceuticalsjuniper pharmaceuticals inc is focused on developing therapeutics that address unmet medical needs in womens health the company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and when appropriate the b regulatory pathway targeted product development investments are enabled by junipers core operating business the crinone® progesterone gel franchise and juniper pharma services which provides highend feeforservice pharmaceutical development and clinical trials manufacturing to clients please visit wwwjuniperpharmacom for more informationjuniper pharmaceuticals™ is a trademark of juniper pharmaceuticals inc in the us and eucrinone® is a registered trademark of merck kgaa darmstadt germany outside the us and of allergan inc in the usforward looking statementsthis press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements relating to the clinical and market potential of junipers product candidates the anticipated clinical programs for junipers product candidates the expected timing of prototype completion and planned indenabling and sheep studies for these product candidates the potential timing of ind submissions for jnp and jnp junipers ability to leverage the b pathway for its product candidates junipers cash position and ability to fund these development programs and operations internally and junipers ability to complete one or more strategic transactions such as a collaboration agreement or new product acquisition management believes that these forwardlooking statements are reasonable as and when made  however such forwardlooking statements involve known and unknown risks uncertainties and other factors that may cause actual results to differ materially from those projected in the forwardlooking statements  these risks and uncertainties include but are not limited to risks associated with the drug development process generally including the timely completion of prototype development and planned indenabling and sheep studies risks associated with the outcomes of the prototype development efforts and planned indenabling and sheep studies and whether they support further development of junipers product candidates risks associated with the regulatory review process including the risk that the fda does not ultimately accept junipers proposed clinical program for jnp the outcomes of planned clinical trials and the regulatory review process the risk that the results of previously conducted studies involving junipers  product candidates will not be repeated or observed in ongoing or future studies or following commercial launch if such product candidates are approved risks associated with obtaining maintaining and protecting intellectual property risks associated with juniper pharmaceuticals ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties the risk of competition from currently approved therapies and from other companies developing products for similar uses risk associated with juniper pharmaceuticals ability to manage operating expenses andor obtain additional funding to support its business activities and risks associated with juniper pharmaceuticals dependence on third parties  for a discussion of certain risks and uncertainties associated with juniper pharmaceuticals forwardlooking statements please review the companys reports filed with the sec including but not limited to its annual report on form ka for the period ended december   and quarterly report on form q for the period ended september   as filed with the sec on november   readers are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date on which they are made these statements are based on managements current expectations and juniper pharmaceuticals does not undertake any responsibility to revise or update any forwardlooking statements contained herein except as expressly required by law investor contactamy raskopf director corporate communications juniper pharmaceuticals inc    irjuniperpharmacommedia contact  amy covino tell med strategies    amycovinotmstratcomto receive junipers press releases sec filings or calendar alerts by email click here follow us on linkedin  to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesjuniperpharmaceuticalsunveilsstrategicandproductdevelopmentobjectivesforhtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextab inbev bud earnings and revenues miss estimates in qzacksengineer finds pattern makes millions in stocksmoney morningsponsoredjeff bezos’ brief stint as world’s richest human ends with amazon’s secondquarter whifftechcrunchwill phillips  psx disappoint this earnings seasonzacksshould you always finish a course of antibioticsprimadiscover it  out of  avg by k customersdiscover cardsponsoredunder armour uaa to report q earnings what lies aheadzacksanthony scaramuccis wife reportedly filed for divorce because he was hellbent on joining trumpbusiness insidermainstream model  holds promise  and peril  for teslaassociated pressthis will be in everyones household by banyan hillsponsoredthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderchevron and exxon mobil have a tough path ahead nyse traderyahoo finance videostocks mixed after heavy earnings weekenter a name wait  seconds brace yourselftruth findersponsoredhere are the us targets north korea most likely wants to nukebusiness insiderthe real reason overseas manufacturing is coming to americayahoo financenorth korea says nd icbm test puts entire us in rangejohn doesnt that little fat kid know that if he actually fires a missile at something other than water his country will just be annihilatedjoin the conversation  k juniper pharmaceuticals reports second quarter  financial resultshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballjuniper pharmaceuticals reports second quarter  financial resultspr newswireaugust  reblogsharetweetshareboston aug   prnewswire  juniper pharmaceuticals inc jnp juniper or the company a womens health therapeutics company today announced financial and other results for the threemonth period ended june   recent highlights includeproduct and service revenue increased  and  respectively versus the second quarter of balance sheet remains strongcrinone® progesterone gel approved in japan under the brand onecrinone®completed enrollment of phase b trial of col  lidocaine vaginal gel in women undergoing a minimally invasive pipelledirected endometrial biopsytwo phase  studies of col published in the international peerreviewed medical journal clinical pharmacology in drug developmentphase  proofofconcept study demonstrating the ability of junipers intravaginal ring to successfully deliver the nine amino acid peptide leuprolide published in the influential peerreviewed journal of controlled release andalicia secor appointed president and ceo and a director of the company juniper pharmaceuticals inc prnewsfotojuniper pharmaceuticals incmorei am very excited to join the company and congratulate the team on a strong second quarter said alicia secor junipers president and ceo  i look forward to building on this momentum as we work to transform juniper into a leading global womens health companystrong growth of the exus crinone franchise and juniper pharma services drove revenue up  to  million for the second quarter of  versus the same period last year said george o elston junipers chief financial officer  this solid yeartodate performance has enabled us to maintain a stable healthy cash position while advancing our proprietary rd programswe are uniquely positioned to leverage our worldclass service and platform capabilities to develop and commercialize important new therapeutics for women ms secor continued i look forward to advancing our current product candidates and expanding our portfolio to fulfill our mission to deliver valueadded treatments that meet the unique and underserved healthcare needs of womenthe company continues to expect to report topline results of its recentlycompleted phase b clinical trial of col  lidocaine bioadhesive vaginal gel this quarter and assuming positive outcomes to advance this candidate into phase  in if successful col is expected to fill an unmet need for pain management in women undergoing minimallyinvasive gynecologic procedures  there are over seven million such procedures performed annually in the united states with no standard of care for pretreatment analgesiajunipers intravaginal ring ivr programs continue to advance toward clinical development  the most advanced ivr product candidate is jnp an oxybutynin ivr for the treatment of overactive bladder in women  indenabling studies are underway including a study defined in the companys preind meeting with the fda to evaluate the pharmacokinetics of jnp in a representative animal modelthe company is accelerating the chemistry manufacturing and controls cmc and production scaleup for jnp beyond its existing inhouse capacity to further develop the gotomarket formulation and commercial manufacturing process ahead of its ind filing which is now expected in   this activity is intended to reduce cmcrelated risks as jnp moves through clinical trials and toward commercialization in the  billion us overactive bladder marketsecond quarter financial resultssecond quarter total revenues increased  to  million compared with  million for the quarter ended june    product revenues were  million an increase of  million or  versus the second quarter of last year driven by continued inmarket growth and new market sales of crinone® progesterone gel by merck kgaa darmstadt germany service revenues from juniper pharma services were  million an increase of  million or  versus the second quarter of last year as we experienced continued strong growth in customer volume  royalty revenues based on allergans sales of crinone® were essentially unchanged at  millionread moregross profit increased to  million as compared with  million in the prior year quartertotal operating expenses were  million in the second quarter of  a  million increase as compared to the prior year quartersales and marketing costs increased  million to  million in the second quarter of  reflecting continued investment in the us market by juniper pharma services the  million increase in rd spending as compared to the prior year quarter was predominantly driven by costs associated with the phase b clinical trial of col rd expense also includes preclinical development costs for the ivr pipeline product candidates jnp oxybutynin ivr jnp estradiol  progesterone ivr for symptoms of menopause and jnp progesterone ivr for the prevention of preterm birththe  million increase in general and administrative costs as compared to the prior year quarter was primarily driven by the creation of an internal business development function that was not in place in  along with costs associated with ceo succession and organizational growthjuniper recorded a net loss of  million or  per diluted share in the second quarter of  compared to a net loss of  million or  per diluted share in the same period of liquiditycash and cash equivalents were  million as of june   versus  million at march   and  million at december    the decrease in cash and cash equivalents was primarily the result of capital expenditures  outlookbased on yearto date revenues and expectations for the second half of the year juniper now anticipates fullyear  revenue growth in the low to midteen percentage range over  resultsconference callas previously announced junipers management will hold a conference call to discuss financial results for the second quarter ended june   as follows date thursday august   time  am edt dialin numbers toll free   us   canada or international   webcast live  archive wwwjuniperpharmacom under investors or click here the teleconference replay will be available at approximately one hour after completion through thursday august   at   us   canada or   international the conference id for the replay is  the archived webcast will be available for one year via the aforementioned urlsabout juniper pharmaceuticalsjuniper pharmaceuticals inc is focused on developing therapeutics that address unmet medical needs in womens health  the company is advancing a pipeline of proprietary product candidates that leverage novel intravaginal drug delivery technologies  junipers commercial product crinone®  progesterone gel is marketed by merck kgaa darmstadt germany in over  countries worldwide and by allergan inc in the us please visit wwwjuniperpharmacom for more informationjuniper pharmaceuticals™ is a trademark of juniper pharmaceuticals inc in the us and eucrinone® is a registered trademark of merck kgaa darmstadt germany outside the us and of allergan inc in the usonecrinone® is a registered trademark of merck kgaa darmstadt germanyus oab market data source technavio insights  global overactive bladder therapeutics market report  httpwwwtechnaviocomreportglobaloveractivebladdertherapeuticsmarketforward looking statementsthis press release contains forwardlooking statements within the meaning of the private securities litigation reform act of  including statements relating to anticipated future financial performance the timing of clinical trials for junipers product candidates and the announcement of results from these trials and the potential of junipers ivr to improve the delivery of therapeutics to women  management believes that these forwardlooking statements are reasonable as and when made  however such forwardlooking statements involve known and unknown risks uncertainties and other factors that may cause actual results to differ materially from those projected in the forwardlooking statements  these risks and uncertainties include but are not limited to risks associated with the drug development process generally including the outcomes of planned clinical trials and the regulatory review process the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies or following commercial launch if such product candidates are approved risks associated with obtaining maintaining and protecting intellectual property risks associated with juniper pharmaceuticals ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties the risk of competition from currently approved therapies and from other companies developing products for similar uses risk associated with juniper pharmaceuticals ability to manage operating expenses andor obtain additional funding to support its business activities and risks associated with juniper pharmaceuticals dependence on third parties  for a discussion of certain risks and uncertainties associated with juniper pharmaceuticals forwardlooking statements please review the companys reports filed with the sec including but not limited to its annual report on form k for the period ended december   and quarterly report on form q for the period ended march   readers are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date on which they are made these statements are based on managements current expectations and juniper pharmaceuticals does not undertake any responsibility to revise or update any forwardlooking statements contained herein except as expressly required by law contactamy raskopf director corporate communications juniper pharmaceuticals inc    irjuniperpharmacommedia amy covino tell med strategies    amycovinotmstratcomto receive junipers press releases sec filings or calendar alerts by email click herefollow us on linkedin  tables follow  juniper pharmaceuticals inc condensed consolidated statements of operations unaudited in thousands except per share data three months ended june  six months ended june      revenues product revenues         service revenues     royalties     total net revenues     cost of product revenues     cost of service revenues     total cost of revenues     gross profit     operating expenses sales and marketing     research and development     general and administrative     total operating expenses     loss from operations     interest expense net     other income net     loss before income taxes     income tax provision     net loss         diluted net loss per share         diluted weighted average shares outstanding     basic net loss per share         basic weighted average shares outstanding        juniper pharmaceuticals inc condensed consolidated balance sheets in thousands june  december    assets cash and cash equivalents     accounts receivable net   inventories   prepaid expenses and other current assets   total current assets   property and equipment net   intangible assets net   goodwill   other assets   total assets     liabilities and stockholders equity accounts payable     accrued expenses and other   deferred revenue   notes payable   total current liabilities   deferred revenue net of current portion   notes payable net of current portion   other noncurrent liabilities   total liabilities   commitments and contingencies series c preferred stock   total stockholders equity   total liabilities and stockholders equity      logo  httpphotosprnewswirecomprnhlogoto view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesjuniperpharmaceuticalsreportssecondquarterfinancialresultshtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextshould you always finish a course of antibioticsprimathis will be in everyones household by banyan hillsponsoredanthony scaramuccis wife reportedly filed for divorce because he was hellbent on joining trumpbusiness insidermainstream model  holds promise  and peril  for teslaassociated pressthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredchevron and exxon mobil have a tough path ahead nyse traderyahoo finance videostocks mixed after heavy earnings weekhere are the us targets north korea most likely wants to nukebusiness insiderdiscover it  out of  avg by k customersdiscover cardsponsoredthe real reason overseas manufacturing is coming to americayahoo financetrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insidermy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videocardiologist  foods you should quit immediatelygundry mdsponsoredblue apron bullish calls not all theyre cooked up to beapnewsbreak yellowstone park cracks down on sex harassmentassociated pressnorth korea says nd icbm test puts entire us in rangejohn doesnt that little fat kid know that if he actually fires a missile at something other than water his country will just be annihilatedjoin the conversation  k  juniper pharmaceuticals  investor relations overview corporate homeinvestor relations overviewcorporate profilejuniper pharmaceuticals nasdaq jnp address unmet and underserved medical needs in womens health our product pipeline leverages our highly differentiated intravaginal ring ivr technology which we expect will offer multiple benefits to patients current b candidates include jnp an oxybutynin ivr for the treatment of overactive bladder in women jnp a combination estradiol  progesterone ivr for hormone replacement therapy and jnp a natural progesterone ivr for the prevention of preterm birth our rd programs are supported by cash flow generated by crinone® progest  more stock quote jnp common stock exchangenasdaq cm us dollarpricechange  volumedata as of   pm etminimum  minute delayrefresh quotewebcastq  juniper pharmaceuticals inc earnings conference call live at  pm etq  juniper pharmaceuticals inc earnings conference callthursday august    pm et  webcast presentation helpclick here for webcastadd to calendar help javascript must be enabled to use this feature  click here to add this event to your calendarjnp corporate overviewrecent newsmore datetitle juniper pharmaceuticals to report second quarter  results on august  juniper pharmaceuticals announces results of  annual meetingjuniper pharmaceuticals reports first quarter  financial and operating resultsjuniper pharmaceuticals to report first quarter  results on may